MAESTrO: CADTH calls for patient input on submissions for 2 new medicines for use by patients with HIV infection

Posted by Michael Wonder on 06 Feb 2016

CADTH calls for patient input on submissions for 2 new medicines for use by patients with HIV infection

5 February 2016 - CADTH has received notice of pending submissions from Theratechnologies for Egrifta (tesamorelin acetate) for lipodystrophy in HIV-infected patients and from Gilead for tenofovir disoproxil fumarate with emtricitabine (Truvada) for pre-exposure prophylaxis of HIV-1 infection.

For more details, go to: https://www.cadth.ca/tesamorelin

Posted by:

Michael Wonder

Posted in:

Medicine , Health technology assessment , Combination product , Canada , Submission , HIV infection